IL237745A0 - Use of lequinimod to reduce damage to the thalamus in multiple sclerosis - Google Patents

Use of lequinimod to reduce damage to the thalamus in multiple sclerosis

Info

Publication number
IL237745A0
IL237745A0 IL237745A IL23774515A IL237745A0 IL 237745 A0 IL237745 A0 IL 237745A0 IL 237745 A IL237745 A IL 237745A IL 23774515 A IL23774515 A IL 23774515A IL 237745 A0 IL237745 A0 IL 237745A0
Authority
IL
Israel
Prior art keywords
laquinimod
multiple sclerosis
thalamic damage
reducing thalamic
reducing
Prior art date
Application number
IL237745A
Other languages
English (en)
Hebrew (he)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Massimo Filippi, Giancarlo Comi, Maria Assunta Rocca filed Critical Teva Pharma
Publication of IL237745A0 publication Critical patent/IL237745A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
IL237745A 2012-10-12 2015-03-15 Use of lequinimod to reduce damage to the thalamus in multiple sclerosis IL237745A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12
PCT/US2013/064061 WO2014058979A2 (en) 2012-10-12 2013-10-09 Laquinimod for reducing thalamic damage in multiple sclerosis

Publications (1)

Publication Number Publication Date
IL237745A0 true IL237745A0 (en) 2015-05-31

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237745A IL237745A0 (en) 2012-10-12 2015-03-15 Use of lequinimod to reduce damage to the thalamus in multiple sclerosis

Country Status (18)

Country Link
US (2) US20140107154A1 (enExample)
EP (1) EP2961406A4 (enExample)
JP (1) JP2015533163A (enExample)
KR (1) KR20150080509A (enExample)
CN (1) CN105263325A (enExample)
AR (1) AR092993A1 (enExample)
AU (2) AU2013329348A1 (enExample)
BR (1) BR112015007782A2 (enExample)
CA (1) CA2884272A1 (enExample)
CL (2) CL2015000732A1 (enExample)
EA (1) EA201590726A1 (enExample)
HK (1) HK1218865A1 (enExample)
IL (1) IL237745A0 (enExample)
MX (1) MX2015004564A (enExample)
PE (1) PE20151435A1 (enExample)
SG (1) SG11201501874TA (enExample)
TW (1) TW201420101A (enExample)
WO (1) WO2014058979A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
KR20150119227A (ko) * 2013-02-15 2015-10-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
BR112019004791A2 (pt) * 2016-09-13 2019-06-04 Intekrin Therapeutics Inc tratamento de esclerose múltipla com chs-131
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
JP2009543823A (ja) * 2006-07-17 2009-12-10 ノバルティス アクチエンゲゼルシャフト 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
PE20140872A1 (es) * 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Also Published As

Publication number Publication date
SG11201501874TA (en) 2015-05-28
CA2884272A1 (en) 2014-04-17
WO2014058979A3 (en) 2015-08-20
CN105263325A8 (zh) 2017-07-14
KR20150080509A (ko) 2015-07-09
CL2015000732A1 (es) 2015-08-07
MX2015004564A (es) 2015-07-21
US20160296511A1 (en) 2016-10-13
JP2015533163A (ja) 2015-11-19
HK1218865A1 (zh) 2017-03-17
TW201420101A (zh) 2014-06-01
AU2017203896A1 (en) 2017-06-29
US20140107154A1 (en) 2014-04-17
WO2014058979A8 (en) 2015-04-16
CN105263325A (zh) 2016-01-20
PE20151435A1 (es) 2015-10-15
AR092993A1 (es) 2015-05-13
CL2016002873A1 (es) 2017-04-17
EP2961406A4 (en) 2017-01-04
EA201590726A1 (ru) 2015-10-30
EP2961406A2 (en) 2016-01-06
BR112015007782A2 (pt) 2017-07-04
AU2013329348A1 (en) 2015-05-28
WO2014058979A2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
SG11201501874TA (en) Laquinimod for reducing thalamic damage in multiple sclerosis
ZA201504200B (en) Beta-lactamase inhibitors
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
EP2764428A4 (en) MULTI-DIMENSIONAL INTERFACE
EP2844523A4 (en) HALTEDOCK
GB201212096D0 (en) Improved cleaning formulation and method
ZA201402148B (en) Coolant formulations
SG11201502680QA (en) Benzamides
GB201208548D0 (en) Compound and method
IL229262A0 (en) Superstructure and methods for its production
PL2748267T3 (pl) Sposób ochrony powierzchni
IL235919A0 (en) inhibitors of fbxo3
PL2870206T3 (pl) Środek usuwający oznaczenia
PL2667710T3 (pl) Kompozycja owadobójcza i związane z nią sposoby
PL2805796T3 (pl) Sposób szlifowania
PL2527081T3 (pl) Centrum obróbkowe i sposób obróbki
IL232938A0 (en) A pharmaceutical preparation used to reduce damage caused by free radicals
EP2847733A4 (en) PROCEDURE AND ARRANGEMENTS FOR THE EXCHANGE OF TRADEMARKED PRODUCTS
IL236154A0 (en) compound and method
ZA201406489B (en) Workpiece positioning structure and workpiece positioning method
SG10201703786YA (en) Nox removal method
SMT202100100T1 (it) Metodi e composizioni per inibire una patologia associata a polyomavirus
GB201117816D0 (en) CE No Damage Tools
GB201215501D0 (en) Social multi-media tool
GB201109246D0 (en) New removal tool and barrier design